Posted inwhat

What is Diazepam? Unveiling the Uses, Side Effects, and Mechanism of Action of Valium

No Comments

Diazepam, commonly recognized under the brand name Valium, is a medication belonging to the benzodiazepine class of drugs. It holds FDA approval for a wide array of conditions, including the management of anxiety disorders, providing short-term relief from anxiety symptoms, alleviating spasticity linked to upper motor neuron disorders, serving as an adjunctive therapy for muscle spasms, easing preoperative anxiety, managing specific patients with refractory epilepsy, and acting as an adjunct in severe recurrent convulsive seizures and status epilepticus. Beyond its approved uses, diazepam is also utilized off-label for sedation in intensive care units (ICUs) and for the short-term management of spasticity in children diagnosed with cerebral palsy. This comprehensive guide aims to explore the multifaceted nature of diazepam, detailing its mechanism of action, potential adverse effects, both approved and non-approved applications, dosage guidelines, pharmacodynamics, pharmacokinetics, necessary monitoring parameters, and significant drug interactions. This information is crucial for all members of the healthcare team involved in the care of patients who are prescribed diazepam for any of its indicated uses.

Diazepam: Approved Indications and Uses

Diazepam, an anxiolytic benzodiazepine, was first patented and introduced to the US market in 1963. Renowned for its rapid onset and prolonged duration of action, diazepam is frequently prescribed for the treatment of anxiety disorders, alcohol withdrawal, acute repetitive seizures, severe muscle spasms, and spasticity associated with neurological conditions. In the context of acute alcohol withdrawal, diazepam effectively manages symptoms such as agitation, tremors, alcoholic hallucinosis, and delirium tremens.[1] Benzodiazepines, including diazepam, have largely superseded barbiturates in the treatment of anxiety and sleep disorders due to their enhanced safety profile, reduced incidence of side effects, and the availability of flumazenil, an antagonist capable of reversing oversedation in benzodiazepine overdose cases.[2, 3]

The FDA has sanctioned diazepam for the following indications:

  • Anxiety Disorders Management: For the long-term management of generalized anxiety disorder and panic disorder.
  • Short-Term Anxiety Symptom Relief: To provide rapid relief from acute anxiety symptoms.
  • Spasticity Associated with Upper Motor Neuron Disorders: Effective in managing muscle stiffness and spasms resulting from conditions like cerebral palsy and multiple sclerosis.
  • Adjunct Therapy for Muscle Spasms: Used in conjunction with other treatments to relieve muscle spasms.
  • Preoperative Anxiety Relief: Administered before surgery to reduce anxiety and promote relaxation.
  • Management of Refractory Epilepsy: For patients whose epilepsy is not adequately controlled by other treatments.
  • Adjunct in Severe Recurrent Convulsive Seizures and Status Epilepticus: As an additional treatment to control prolonged seizures.
  • Alcohol Withdrawal: To manage agitation, tremors, and delirium tremens associated with alcohol withdrawal.

Furthermore, diazepam is used off-label for:

  • Sedation in the ICU: To induce sedation in critically ill patients in intensive care settings.
  • Short-Term Spasticity Treatment in Children with Cerebral Palsy: To manage muscle spasticity in pediatric cerebral palsy patients.[4]

How Diazepam Works: Mechanism of Action

Benzodiazepines like diazepam exert their therapeutic effects by potentiating the activity of gamma-aminobutyric acid (GABA), a primary inhibitory neurotransmitter in the brain. Diazepam specifically binds to an allosteric site located at the interface between the alpha and gamma subunits on GABA-A receptor chloride ion channels. This allosteric binding of diazepam enhances the frequency at which the chloride channel opens when GABA is also bound, leading to an increased influx of chloride ions into the neuron. The influx of chloride ions causes hyperpolarization of the neuronal membrane, reducing neuronal excitability and resulting in a calming effect.[5]

The specific effects of diazepam are mediated by receptor binding in different areas of the central nervous system:

  • Limbic System: Allosteric binding in the limbic system is primarily responsible for the anxiolytic (anxiety-reducing) effects of diazepam.
  • Spinal Cord and Motor Neurons: Binding within the spinal cord and motor neurons mediates the myorelaxant (muscle-relaxing) properties of diazepam, making it effective in treating muscle spasms and spasticity.
  • Cortex, Thalamus, and Cerebellum: Sedative, amnestic (memory-impairing), and anticonvulsant effects are mediated through receptor binding in the cortex, thalamus, and cerebellum. These actions contribute to diazepam’s use in seizure management, sedation, and preoperative anxiety relief.[6]

Diazepam Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion

Understanding the pharmacokinetics of diazepam is essential for optimizing its clinical use and predicting its effects in the body:

  • Absorption: Following oral administration, diazepam is rapidly and almost completely absorbed, with over 90% bioavailability. Peak plasma concentrations are typically achieved within 1 to 1.5 hours after oral intake. Food consumption can delay and reduce the rate of absorption, increasing the average time to peak concentrations to about 2.5 hours.
  • Distribution: Diazepam is highly lipophilic, allowing it to cross the blood-brain barrier rapidly, contributing to its quick onset of action. It also readily crosses the placental barrier and is found in breast milk. Diazepam and its active metabolites exhibit high plasma protein binding, approximately 98% for diazepam. The volume of distribution ranges from 0.8 to 1.0 L/kg, indicating wide tissue distribution.
  • Metabolism: Diazepam is primarily metabolized in the liver by cytochrome P450 enzymes, mainly CYP2C19 and CYP3A4. It undergoes metabolism into several active metabolites, with desmethyldiazepam (nordiazepam) being the major active metabolite. Other minor active metabolites include temazepam and oxazepam. These active metabolites contribute to diazepam’s prolonged duration of action.
  • Excretion: Diazepam and its metabolites are predominantly excreted in the urine. Diazepam exhibits a biphasic elimination pattern, with an initial distribution phase followed by a prolonged terminal elimination phase. The average half-life of diazepam is around 48 hours, while its major active metabolite, desmethyldiazepam, has a much longer half-life of up to 100 hours. Upon repeated dosing, diazepam can accumulate in the body, leading to a slightly prolonged terminal elimination half-life.

Diazepam Administration and Dosage Guidelines

Diazepam is available in various formulations to suit different clinical needs and routes of administration:

  • Oral Tablets: Available in various strengths for convenient oral administration.
  • Intramuscular (IM) Injections: For situations where oral administration is not feasible or rapid onset is needed, although absorption can be less reliable than oral.
  • Intravenous (IV) Injections: Provide the most rapid onset of action, typically within 1 to 3 minutes, ideal for emergency situations like status epilepticus.
  • Rectal Gel: A convenient formulation for managing acute seizures, particularly in outpatient settings or when IV access is not immediately available.

Dosage Recommendations for Specific Conditions:

  • Acute Ethanol Withdrawal: Initially, 10 mg IM or IV is recommended. If necessary, a follow-up dose of 5 to 10 mg can be administered 3 to 4 hours later. For oral tablets, the initial regimen is 10 mg every 6 to 8 hours for the first 24 hours, followed by 5 mg every 6 to 8 hours as needed.[4]
  • Anxiety: Oral dosage ranges from 2 to 10 mg, administered 2 to 4 times daily. Parenteral administration (IM or IV) can be 2 to 10 mg, repeated every 3 to 4 hours if required.[7]
  • Muscle Spasms: Oral dosage is typically 2 to 10 mg, 3 to 4 times daily. Parenteral administration starts with 5 to 10 mg, followed by another 5 to 10 mg dose in 3 to 4 hours if necessary.[8]
  • Preoperative Anxiety: A single 10 mg IM dose is usually administered before surgery.[9]
  • ICU Sedation (Off-label): A loading dose of 5 to 10 mg is followed by a maintenance dose of 0.03 to 0.10 mg/kg every 0.5 to 6 hours (Barr 2013).
  • Seizures (Adjunctive Therapy): Oral dosage is 2 to 10 mg, 2 to 4 times daily. Rectal gel at 0.2 mg/kg is an option for intermittent seizure management, repeatable every 4 to 12 hours if needed, with usage limits to prevent overuse.
  • Skeletal Muscle Relaxant (Adjunct): 2 to 10 mg, 3 to 4 times daily.
  • Status Epilepticus: IV dosage is 0.15 to 0.20 mg/kg per dose, repeatable once if needed, not exceeding 10 mg per single dose. Rectal administration is 0.2 to 0.5 mg/kg, single dose, not exceeding 20 mg per dose.[10]

Diazepam Use in Specific Patient Populations

Certain patient populations require special considerations when diazepam is prescribed:

  • Renal Impairment: Older adults, who often have reduced renal function, are at higher risk of diazepam and metabolite accumulation. Lower doses are recommended, and monitoring for paradoxical CNS hyperactivity, such as agitation and confusion, is crucial.[11, 12, 13]
  • Hepatic Impairment: Liver disease significantly affects diazepam metabolism, leading to increased half-life and reduced clearance. Dosage adjustments are necessary in patients with hepatic impairment, with careful monitoring for adverse effects.
  • Pregnancy: Diazepam is categorized as FDA pregnancy category D, indicating potential fetal risk. Use during pregnancy is associated with increased risks of congenital malformations, premature birth, and neonatal withdrawal syndrome. “Floppy infant syndrome,” characterized by hypotonia and respiratory distress, is also a concern in newborns exposed to diazepam in the last trimester.[14, 15]
  • Breastfeeding: Diazepam and its metabolites are excreted in breast milk. While short-term use may pose minimal risk, long-term or high doses can lead to accumulation in infants, causing drowsiness, poor feeding, and lethargy. Caution is advised, and temporary cessation of breastfeeding may be considered, especially with preterm infants or repeated diazepam administration.[16, 17]

Diazepam Adverse Effects and Drug Interactions

Like all medications, diazepam carries the risk of adverse effects, and it can interact with other drugs.

Serious Adverse Effects:

  • Respiratory Depression
  • Suicidality[19]
  • Dependence and Abuse
  • Withdrawal Symptoms
  • Cardiovascular Collapse
  • Bradycardia
  • Hypotension
  • Syncope
  • Paradoxical CNS Stimulation (e.g., agitation, aggression)[20]

Common Adverse Effects:

  • Sedation
  • Fatigue
  • Confusion
  • Anterograde Amnesia (difficulty forming new memories)
  • Depression
  • Ataxia (loss of coordination)
  • Irritability
  • Disinhibition
  • Local Injection Site Reaction
  • Headache
  • Tremor
  • Dystonia (involuntary muscle contractions)
  • Urinary Retention or Incontinence
  • Nausea
  • Constipation
  • Diplopia (double vision)
  • Libido Changes
  • Rash
  • Menstrual Irregularities
  • Elevated Liver Enzymes (ALT, AST)[21]

Drug Interactions:

  • CYP450 Enzyme Inhibitors: Drugs that potently inhibit CYP2C19 (e.g., fluoxetine, chloramphenicol) and CYP3A4 (e.g., ketoconazole, protease inhibitors, erythromycin) can increase diazepam levels, potentially leading to enhanced sedation and other adverse effects.
  • CYP450 Enzyme Inducers: Inducers of CYP2C19 (e.g., rifampicin, prednisone) and CYP3A4 (e.g., carbamazepine, phenytoin, St. John’s wort, rifampin, barbiturates) can decrease diazepam levels, potentially reducing its therapeutic efficacy.[22]
  • Opioids: Concomitant use of diazepam and opioids carries a significant risk of respiratory depression, profound sedation, coma, and death. This is highlighted in a boxed warning from the FDA, recommending cautious prescribing of these drugs together.[26]

Diazepam Contraindications and Warnings

Diazepam is contraindicated in certain patient populations and conditions:

  • Hypersensitivity to diazepam or any benzodiazepine.
  • Infants under six months of age.
  • Severe respiratory insufficiency.
  • Myasthenia gravis (unless treating muscle spasms associated with it).
  • Sleep apnea syndrome.
  • Severe hepatic insufficiency.
  • Acute narrow-angle glaucoma (it is permissible in open-angle glaucoma with appropriate therapy).[23, 24]

Boxed Warning:

The FDA has issued a boxed warning regarding the concomitant use of benzodiazepines, including diazepam, and opioids due to the heightened risk of severe respiratory depression, sedation, coma, and death. Prescribing these medications together should be reserved for patients for whom alternative treatment options are inadequate, and doses should be minimized to the lowest effective dose for the shortest duration possible.[26]

Monitoring and Management During Diazepam Therapy

Monitoring is crucial to ensure safe and effective diazepam use:

  • Respiratory and Cardiovascular Status: Monitor for respiratory depression, blood pressure, and heart rate, especially during initial dosing and in patients with respiratory conditions.
  • Anxiety Symptoms and Treatment Response: Regularly assess the patient’s anxiety levels and response to diazepam therapy to adjust dosage as needed.
  • Long-Term Use Monitoring: For chronic diazepam use, monitor liver enzymes, complete blood count (CBC), and for signs of propylene glycol toxicity if using IV formulations, including serum creatinine, BUN, serum lactate, and osmolality gap.[27]
  • Sedation Depth in Critically Ill Patients: In ICU settings, use sedation scales like RASS (Richmond Agitation-Sedation Scale) and CAM-ICU (Confusion Assessment Method for the ICU) to guide and monitor sedation levels.[33]
  • Benzodiazepine Use Disorder (BUD): Monitor patients for signs of BUD, including drug-seeking behavior, tolerance, and withdrawal symptoms, and provide appropriate referrals for addiction treatment if needed. Prescription drug monitoring programs can help identify potential misuse and diversion.[28]

Diazepam Overdose, Abuse Potential, and Propylene Glycol Toxicity

Diazepam Overdose:

Benzodiazepines have a relatively high therapeutic index, but overdose is possible, especially when combined with other CNS depressants like opioids or alcohol. Symptoms of diazepam overdose range from mild (lethargy, confusion) to severe (ataxia, respiratory depression, hypotension, coma). Treatment focuses on airway management, supportive care, and, if necessary, administration of flumazenil, a benzodiazepine antagonist. However, flumazenil can precipitate withdrawal seizures in chronic benzodiazepine users.[3, 14]

Abuse and Dependence:

Diazepam is a Schedule IV controlled substance with a potential for abuse and dependence. Prolonged use, high doses, or use in individuals with a history of substance abuse increases the risk of dependence. Benzodiazepine withdrawal can be severe, including symptoms like anxiety, tremors, seizures, and psychosis. Gradual dose reduction is recommended to minimize withdrawal symptoms upon discontinuation.[25, 29]

Propylene Glycol Toxicity:

Intravenous diazepam formulations contain propylene glycol as a solvent. High doses or prolonged infusions can lead to propylene glycol accumulation, causing anion gap metabolic acidosis and potential organ damage. Monitoring for signs of propylene glycol toxicity is important in patients receiving IV diazepam, especially with prolonged infusions or high doses.[30]

Enhancing Healthcare Team Outcomes with Diazepam Management

Effective and safe use of diazepam requires a collaborative interprofessional healthcare team approach. Clinicians, including physicians, nurse practitioners, and physician assistants, are responsible for appropriate prescribing, considering indications, contraindications, and patient-specific factors. Psychiatrists and neurologists may be consulted for anxiety disorders, spasticity, and epilepsy management, respectively. Pharmacists play a crucial role in medication reconciliation, dosage verification, drug interaction screening, and patient counseling. Nurses are essential for monitoring patients, especially in hospital settings, and for recognizing and managing adverse effects and withdrawal symptoms.[31, 32]

In cases of diazepam overdose, emergency department and critical care teams must work together for rapid diagnosis, stabilization, and treatment, including potential flumazenil administration and respiratory support. Patient education is also paramount. Programs like EMPOWER have demonstrated the effectiveness of direct patient education in reducing inappropriate benzodiazepine use in older adults, highlighting the importance of empowering patients in managing their medications.[34]

By fostering effective communication and collaboration, the interprofessional team can optimize diazepam therapy, minimize risks, and improve patient outcomes. Regular reviews of controlled substance databases and adherence to prescribing guidelines are essential to prevent misuse and dependence, ensuring that diazepam is used responsibly and effectively for its intended therapeutic purposes.[28]

References

  1. Calcaterra NE, Barrow JC. Classics in chemical neuroscience: diazepam (valium). ACS Chem Neurosci. 2014 Apr 16;5(4):253-60. [PMC free article: PMC3990949] [PubMed: 24552479]
  2. Sharbaf Shoar N, Bistas KG, Patel P, Saadabadi A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 29, 2024. Flumazenil. [PubMed: 29262246]
  3. An H, Godwin J. Flumazenil in benzodiazepine overdose. CMAJ. 2016 Dec 06;188(17-18):E537. [PMC free article: PMC5135539] [PubMed: 27920113]
  4. Weintraub SJ. Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal. CNS Drugs. 2017 Feb;31(2):87-95. [PubMed: 28101764]
  5. Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001 Nov;179:390-6. [PubMed: 11689393]
  6. Friedman H, Greenblatt DJ, Peters GR, Metzler CM, Charlton MD, Harmatz JS, Antal EJ, Sanborn EC, Francom SF. Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. Clin Pharmacol Ther. 1992 Aug;52(2):139-50. [PubMed: 1505149]
  7. Vinkers CH, Tijdink JK, Luykx JJ, Vis R. [Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics]. Ned Tijdschr Geneeskd. 2012;155(35):A4900. [PubMed: 22929751]
  8. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jan 24, 2017. Benzodiazepines. [PMC free article: PMC547852] [PubMed: 31643621]
  9. Pekcan M, Celebioglu B, Demir B, Saricaoglu F, Hascelik G, Yukselen MA, Basgul E, Aypar U. The effect of premedication on preoperative anxiety. Middle East J Anaesthesiol. 2005 Jun;18(2):421-33. [PubMed: 16438017]
  10. Crawshaw AA, Cock HR. Medical management of status epilepticus: Emergency room to intensive care unit. Seizure. 2020 Feb;75:145-152. [PubMed: 31722820]
  11. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015 Nov;63(11):2227-46. [PubMed: 26446832]
  12. Vozeh S. [Pharmacokinetic of benzodiazepines in old age]. Schweiz Med Wochenschr. 1981 Nov 21;111(47):1789-93. [PubMed: 6118950]
  13. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019 Apr;67(4):674-694. [PubMed: 30693946]
  14. Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry. 2013 Jan-Feb;35(1):3-8. [PubMed: 23044244]
  15. Dallmann A, Ince I, Coboeken K, Eissing T, Hempel G. A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. Clin Pharmacokinet. 2018 Jun;57(6):749-768. [PubMed: 28924743]
  16. Brandt R. Passage of diazepam and desmethyldiazepam into breast milk. Arzneimittelforschung. 1976;26(3):454-7. [PubMed: 989345]
  17. Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jan 15, 2024. Diazepam. [PubMed: 30000273]
  18. Seldenrijk A, Vis R, Henstra M, Ho Pian K, van Grootheest D, Salomons T, Overmeire F, de Boer M, Scheers T, Doornebal-Bakker R, Ruhé HG, Vinkers CH. [Systematic review of the side effects of benzodiazepines]. Ned Tijdschr Geneeskd. 2017;161:D1052. [PubMed: 29076441]
  19. Dodds TJ. Prescribed Benzodiazepines and Suicide Risk: A Review of the Literature. Prim Care Companion CNS Disord. 2017 Mar 02;19(2) [PubMed: 28257172]
  20. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy. 2004 Sep;24(9):1177-85. [PubMed: 15460178]
  21. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jun 22, 2023. Diazepam (Oral) [PMC free article: PMC547852] [PubMed: 31643207]
  22. Li Y, Ning J, Wang Y, Wang C, Sun C, Huo X, Yu Z, Feng L, Zhang B, Tian X, Ma X. Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36. [PubMed: 29753067]
  23. Park MY, Kim WJ, Lee E, Kim C, Son SJ, Yoon JS, Kim W, Namkoong K. Association between use of benzodiazepines and occurrence of acute angle-closure glaucoma in the elderly: A population-based study. J Psychosom Res. 2019 Jul;122:1-5. [PubMed: 31126405]
  24. Wang SH, Chen WS, Tang SE, Lin HC, Peng CK, Chu HT, Kao CH. Benzodiazepines Associated With Acute Respiratory Failure in Patients With Obstructive Sleep Apnea. Front Pharmacol. 2018;9:1513. [PMC free article: PMC6330300] [PubMed: 30666205]
  25. Soyka M. Treatment of Benzodiazepine Dependence. N Engl J Med. 2017 Mar 23;376(12):1147-1157. [PubMed: 28328330]
  26. McClure FL, Niles JK, Kaufman HW, Gudin J. Concurrent Use of Opioids and Benzodiazepines: Evaluation of Prescription Drug Monitoring by a United States Laboratory. J Addict Med. 2017 Nov/Dec;11(6):420-426. [PMC free article: PMC5680991] [PubMed: 28953504]
  27. Ku LC, Hornik CP, Beechinor RJ, Chamberlain JM, Guptill JT, Harper B, Capparelli EV, Martz K, Anand R, Cohen-Wolkowiez M, Gonzalez D., Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for Status Epilepticus. CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):718-727. [PMC free article: PMC6263663] [PubMed: 30267478]
  28. Manders L, Abd-Elsayed A. Mandatory Review of Prescription Drug Monitoring Program Before Issuance of a Controlled Substance Results in Overall Reduction of Prescriptions Including Opioids and Benzodiazepines. Pain Physician. 2020 Jun;23(3):299-304. [PubMed: 32517396]
  29. Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015 Oct;38(5):152-5. [PMC free article: PMC4657308] [PubMed: 26648651]
  30. Jahn A, Bodreau C, Farthing K, Elbarbry F. Assessing Propylene Glycol Toxicity in Alcohol Withdrawal Patients Receiving Intravenous Benzodiazepines: A One-Compartment Pharmacokinetic Model. Eur J Drug Metab Pharmacokinet. 2018 Aug;43(4):423-430. [PubMed: 29392569]
  31. Zaccara G, Giannasi G, Oggioni R, Rosati E, Tramacere L, Palumbo P., convulsive status epilepticus study group of the uslcentro Toscana, Italy. Challenges in the treatment of convulsive status epilepticus. Seizure. 2017 Apr;47:17-24. [PubMed: 28282553]
  32. Mekonnen AB, McLachlan AJ, Brien JA. Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ Open. 2016 Feb 23;6(2):e010003. [PMC free article: PMC4769405] [PubMed: 26908524]
  33. Taran Z, Namadian M, Faghihzadeh S, Naghibi T. The Effect of Sedation Protocol Using Richmond Agitation-Sedation Scale (RASS) on Some Clinical Outcomes of Mechanically Ventilated Patients in Intensive Care Units: a Randomized Clinical Trial. J Caring Sci. 2019 Dec;8(4):199-206. [PMC free article: PMC6942649] [PubMed: 31915621]
  34. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014 Jun;174(6):890-8. [PubMed: 24733354]

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *